Skip to main content
. 2021 Jan 22;24(2):102089. doi: 10.1016/j.isci.2021.102089

Figure 5.

Figure 5

Rituximab more than obinutuzumab induces pro-survival signals

(A) Immunoblot detection of phospho-AKT Ser473 and phospho-PRAS40 Thr246 in SU-DHL4 cells treated with 2.5 μg/ml rituximab (R), rituximab F(ab‘)2 fragments (R F(ab‘)2), trastuzumab (T), or obinutuzumab (O) for 1 h relative to untreated control samples (Ctrl). Shown are representative results from one of four experiments.

(B) Calculated AUCs for phosphopeptide ions containing the phosphorylation site Ser99 (top) or Ser118 (bottom) on BAD. Line indicates mean. ∗p<0.05, ∗∗p<0.01, ∗∗∗p<0.001, ns = not significant, as calculated by unpaired non-parametric t tests.